Using methadone for opiate dependence: What counselors need to know. Matthew A. Torrington, MD COMP Conference September 11, 2007.

Slides:



Advertisements
Similar presentations
Substance Related Disorders
Advertisements

Dosing and patient management requirements during induction, stabilization, and detoxification with buprenorphine Matthew A. Torrington MD Clinical Research.
Treatment of opioid dependence during pregnancy Judith Martin, MD Medical Director The 14 th Street Clinic, Oakland
Pharmacological Treatment of Opioid Dependence during Pregnancy: Methadone and Buprenorphine Overview Karol Kaltenbach, PhD Maternal Addiction Treatment.
OPIOIDS I. Where do they come from? / synthesized in 1803
DSM – 5 Substance-Related and Addictive Disorders
Facts In 2008, an estimated 20.1 million Americans aged 12 or older were current (past-month) illicit drug users. (8.0% of the population) million.
Why Not Use the DSM-IVR for Diagnosing Addiction? Reason #147: Inadequacies of using qualitative indices for a quantitative problem.
Copyright Alcohol Medical Scholars Program 1 Opioid Agonist Treatment: “Trading one substance for another?” Joseph Sakai, M.D.
Methadone in Opioid Addiction David Kan, M.D. University of California San Francisco VA Medical Center San Francisco.
What are “opiates”? heroin Morphine MS Contin oxycodone Oxycontin & Percocet hydrocodone Vicodin Codeine Tylenol # 3 hydromorphone Dilaudid meperidine.
Diagnosis and Treatment of Opioid Dependence
The Medical Model: Addiction is a Brain Disease
Role of Medications in Recovery and the Prevention of Relapse Mark Publicker, MD FASAM Medical Director, Mercy Recovery Center, Westbrook Maine.
Medical Model of Addiction
INTRODUCTION TO ADDICTION Benjamin R. Nordstrom, M.D., Ph.D. Assistant Professor of Psychiatry Geisel School of Medicine at Dartmouth Director of Addiction.
Diagnosis And Treatment Of Prescription Opioid Dependence Steven W. Clay, D.O. Associate Professor, Department of Family Medicine Ohio University College.
Chapter 4 Screening and Assessment of Alcohol/Drug Problems.
©2010 McGraw-Hill Higher Education. All rights reserved. Chapter 4 Definitions of Substance Abuse, Dependence, and Addiction.
Buprenorphine in the treatment of addiction Matthew A. Torrington MD Clinical Research Physician UCLA: Integrated Substance Abuse Programs Matrix Institute.
DOUGHNUTSDOUGHNUTS. Opioid Agonist Therapy The Skinny on Methadone et al.
Assessment of Substance Use Disorders
Copyright © 2007 by The McGraw-Hill Companies, Inc. All rights reserved. Chapter 17 Substance-Related Disorders – Focus on Alcoholism.
Buprenorphine and the Office- Based Treatment of Opiate Dependence Matthew A. Torrington, MD AAFP ASAM Medical Director Matrix Institute, Narcotic Treatment.
BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS Module III – Buprenorphine 101.
Medication Assisted Therapy for Opioid Addiction: Methadone and Buprenorphine Andrew J. Saxon, M.D. Veterans Affairs Puget Sound Health Care System and.
OPIOID SUBSTITUTION THERAPY
OPIOIDS I. Where do they come from? –poppy plant: from middle east and Asia –dried sap from plant is opium; cultivated annually BUT plant produces drug.
Buprenorphine: An Introduction Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006
OPIOIDS I. Where do they come from? –poppy plant: from middle east and Asia –dried sap from plant is opium; cultivated annually BUT plant produces drug.
Opioid Dependence Anne Kalvik Pearl Isaac. Learning Objectives 1.To develop an understanding of opioid dependence issues including tolerance, abuse, toxicity,
FIVE MINUTES TO MAKE A DIFFERENCE Presentation by: Mark Barnes.
Module IV: Identification of Patients for Buprenorphine Treatment BUPRENORPHINE TREATMENT: A Training For Multidisciplinary Addiction Professionals.
Medical issues about Methadone : What the counselor needs to know
DRUGS OF ABUSE Reynaldo J. Lesaca, M.D. Reynaldo J. Lesaca, M.D.
Defining substance abuse Health Psychology. Introduction to Substances.
Module 1 General introduction to substitution treatment.
Chapter 8 Narcotics. Historical Perspectives The term narcotics is from the Greek word meaning stupor Throughout history opium figured prominently in.
Substance Use Disorders. A maladaptive pattern of substance use leading to clinically significant social, emotional, or occupational impairment or distress.
Opioid Pharmacotherapy: An Introduction Walter Ling, MD Integrated Substance Abuse Programs (ISAP) UCLA International Symposium on Drug Abuse and Addictive.
Special patient groups Module 5. Introduction Worldwide, the majority of people in substitute treatment are men between Even they do not form a.
Substance abuse. Definition It’s a mental disorder that shows symptoms and maladaptive behavioral changes with the use of substances that affect the CNS.
Principles of Effective Drug Addiction Treatment Health 10 The Truth About Drugs Ms. Meade.
Opioid Treatment Basics for Counselors Thomas E. Freese, PhD Pacific Southwest Addiction Technology Transfer Center UCLA Integrated Substance Abuse Programs.
Buprenorphine {Suboxone®, Subutex®}
Chronic Pain Management Harald Lausen, DO, MA FCM Clerkship SIU School of Medicine.
Benjamin Nordstrom MD, PhD VP, Medical Director for Program Development Phoenix House Foundation.
Suboxone and Opioid Trends Joseph Merrill M.D., M.P.H. University of Washington June 16, 2009.
Addiction vs. Physical Dependence Katie Ulrich Clinical Psychologist.
Medications for the Treatment of Opioid Addiction Robert P. Schwartz, M.D. Friends Research Institute.
Medication Assisted Treatment Daniel T. Brown, D.O. Medical Director, Meridian HealthCare.
Gregory S. Brigham, Ph.D., CEO
Medical Assisted Treatment
Medication-Assisted Therapy at Coleman Profession Services
What are “opiates”? heroin
Methadone and Suboxone
COMMONLY USED TERMS DR. JOSEPH B. FAMA FPSMS CLINICAL DEPARTMENT HEAD DOH-DRUG TREATMENT AND REHABILITATION CENTER.
Drug Use as a Social Problem
DSM-IV-TR, APA, 2000 Criteria for Substance Dependence:
Medication-Assisted Treatment 101: Breaking the Stigma
Substance Use Disorders
Pain Management: Patients Maintained on Buprenorphine
Drug Abuse Munir Gharaibeh, MD, PhD, MHPE
ADDICTION
Are you sick and tired of being sick and tired?
Medically assisted treatment
Medication Assisted Treatment of Opioid Use Disorder
Bassett-UMass MAT ECHO.
Opiate misuse among our seniors
Presentation transcript:

Using methadone for opiate dependence: What counselors need to know. Matthew A. Torrington, MD COMP Conference September 11, 2007

AAPainMed,APainS, ASAM defined ADDICTON in 2001 Addiction is a primary, chronic, neurobiologic disease, with genetic, psychosocial, and environmental factors influencing its development and manifestations. It is characterized by behaviors that include one or more of the following: impaired control over drug use, compulsive use, continued use despite harm, and craving Savage et al., 2001

Premise of this Presentation Drug Dependence is a brain disease with behavioral manifestations that occur in a social context The brain disease should be treated with pharmacotherapy Dysfunctional behavior should be addressed with psychosocial interventions

Substance Dependence: A Disease With Many Interacting Causes WHO. Neuroscience of Psychoactive Substance Use And Dependence SUBSTANCE DEPENDENCE SUBSTANCE DEPENDENCE Genetic Biological Social Cultural Psychological Environmental

Pseudoaddiction operationally defined as aberrant drug-related behaviors that make patients with chronic pain look like addicts. these behaviors stop if opioid doses are increased and pain improves (Weissman and Haddox, 1989). This indicates that the aberrant drug-related behaviors were actually a search for relief Little data on the subject, but evidence in rats

Addiction is NOT: Physical dependence - characteristic withdrawal syndrome emerges upon decreased blood levels of substance or antagonist administration Tolerance - increasing amount of drug needed over time to induce the same effect Both are neuroadaptive states resulting from chronic drug administration

What are opiates? a.) Inducing sleep; somniferous; narcotic; hence, anodyne; causing rest, dullness, or inaction; as, the opiate rod of Hermes. (n.) Originally, a medicine of a thicker consistence than syrup, prepared with opium. (n.) Any medicine that contains opium, and has the quality of inducing sleep or repose; a narcotic. (n.) Anything which induces rest or inaction; that which quiets uneasiness.

Schematic of Opiate Receptor Source: Goodman and Gillman 9 th ed, p. 526

Effect of Common Opiates at mu receptor Heroin, morphine, methadone Buprenorphine Naltrexone (Revia, Vixo) Nalmefene naloxone Agonist Partial Agonist Antagonist

A maladaptive pattern of substance use, leading to clinically significant impairment or distress, as manifested by three (or more) of the following, occurring at any time in the same 12-month period: DSM-IV Criteria for Substance Dependence

Physiologic Criteria: 1. Tolerance, as defined by either of the following: a) a need for markedly increased amounts of the substance to achieve intoxication or the desired effect, or b) markedly diminished effect with continued use of the same amount of the substance 2. Withdrawal, as manifested by either of the following: a) the characteristic withdrawal syndrome for the substance, or b) the same (or closely related) substance is taken to relieve or avoid withdrawal symptoms DSM-IV Criteria for Substance Dependence

Behavioral Criteria: 3. The substance is often taken in larger amounts or over a longer period than was intended 4. There is a persistent desire or unsuccessful efforts to cut down or control substance use 5. A great deal of time is spent in activities necessary to obtain the substance, use the substance, or recover from its effects DSM-IV Criteria for Substance Dependence

Behavioral Criteria: (Cont’d) 6. Important social, occupational, or recreational activities are given up or reduced because of substance use 7. The substance use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance DSM-IV Criteria for Substance Dependence

Prevalence 3,744,000 persons in US reported using heroin at least once in their lifetime (2003 NSDUH) 149,000 new users (1999) 980,000 persons using heroin at least weekly (1998) 810,000 to 1,000,000 chronic users of heroin (ONDCP 2003) Opioid abuse

810,000 to 1,000,000 chronic users of heroin 200,000± patients receiving methadone maintenance treatment 1998 NIH Consensus Statement on Appropriate Treatment of Opiate Dependence called for increased access to pharmacotherapy. Gaps in current treatment of opioid dependence

Number of new non-medical users of therapeutics (NSDUH, 2002)

Diacetylmorphine (Heroin) Hydromorphone (Dilaudid) Oxycodone (OxyContin, Percodan, Percocet, Tylox) Meperidine (Demerol) Hydrocodone (Lortab, Vicodin) Commonly Abused Opioids

Morphine (MS Contin, Oramorph) Fentanyl (Sublimaze) Propoxyphene (Darvon) Methadone (Dolophine) Codeine Opium Commonly Abused Opioids (continued)

Forearm Injection Drug Abuse Photo: C. Redis

Mortality Caused by IV Drug Use  Methods: 1,769 not in Tx IDUs in Portland, OR interviewed in Search of death certificates in  Results: 33 (1.87%) died — 39% OD — 15% trauma — 12% infection — 12% Intracranial hemorrhage — 9% cirrhosis  Interpretation: Age-adjusted relative risk of death=8.3 McAnulty et al., 1995

Forearm Injection Drug Abuse Photo: C. Redis

MEDICAL COMPLICATIONS OF HEROIN ADDICTION  FROM DIRECT DRUG EFFECT Coma Pulmonary Edema Respiratory Arrest  FROM UNSTERILE NEEDLE USE AND SHARING AIDS Hepatitis Sepsis  FROM LIFESTYLE STDs TB

Shoulder Abcess postincision and drainage Injection Drug Abuse Photo: C. Redis

Antecubital Fossa Injection Drug Abuse Photo: C. Redis

Talking to patients about addiction treatment models Recovery Psychodynamic Behavioral Spiritual Medical

ADDICTION AS A CHRONIC ILLNESS Chronic relapsing condition which untreated may lead to severe complications and death.

ADDICTION AS CHRONIC DISEASE: IMPLICATIONS It is treatable but not curable. Adjustment to diagnosis is part of patient’s task. There is a wide spectrum of severity. Retention in treatment is key. Best treatment is integrated.

Four questions patients ask: How is methadone better for me than heroin? What is the right dose of methadone for me? How long should I stay on methadone? What are the side effects of methadone?

Four questions patients ask: How is methadone better for me than heroin? What is the right dose of methadone for me? How long should I stay on methadone? What are the side effects of methadone?

How is methadone better than heroin? Legal Avoids needles Known amount ingested

Dose Response Time “Loaded” “High” Normal Range “Comfort Zone” “Sick” Methadone Simulated 24 Hr. Dose/Response At steady-state in tolerant patient 0 hrs. 24 hrs. “Abnormal Normality” Subjective w/d Objective w/d Opioid Agonist Treatment of Addiction - Payte

How is methadone better than heroin? Legal Avoids needles Known amount ingested Slow onset: no “rush” Long acting: can maintain “comfort” or normal brain function Stabilized physiology, hormones, tolerance

Four questions patients ask: How is methadone better for me than heroin? What is the right dose of methadone for me? How long should I stay on methadone? What are the side effects of methadone?

What is the right dose? Eliminate physical withdrawal Eliminate ‘craving’ Comfort/function: usually trough is ng/ml, peak no more than twice the trough. Not over-sedated Blocking dose

Dose Response Time “Loaded” “High” Normal Range “Comfort Zone” “Sick” Methadone Simulated 24 Hr. Dose/Response At steady-state in tolerant patient 0 hrs. 24 hrs. “Abnormal Normality” Subjective w/d Objective w/d Opioid Agonist Treatment of Addiction - Payte trough

Ref: J. C. Ball, November 18, 1988 Slide adapted from Tom Payte

“How Much???? Enough!!!” Tom Payte, MD

Four questions patients ask: How is methadone better for me than heroin? What is the right dose of methadone for me? How long should I stay on methadone? What are the side effects of methadone?

Relapse to IV drug use after MMT 105 male patients who left treatment Percent IV Users Treatment Months Since Stopping Treatment Opioid Agonist Treatment of Addiction - Payte Adapted from Ball & Ross - The Effectiveness of Methadone Maintenance Treatment, 1991

“How Long??? Long Enough!!” Tom Payte, MD

Four questions patients ask: How is methadone better for me than heroin? What is the right dose of methadone for me? How long should I stay on methadone? What are the side effects of methadone?

Opiate effects, physical Predictable physical effects of administering opiates: Tolerance: the body becomes efficient in processing the drug and requires ever higher doses to produce the desired effect. Dependence: when the drug is discontinued there are typical withdrawal signs and symptoms.

Side effects of methadone: General opiate effects: Sedation/stimulation Maintained phys. dependence (stable) hypogonadism (not as severe as with heroin, may be dose dependent) Constipation Slight QTc prolongation on ECG (Martell etal) Sweating Methadone treatment tied to regulated clinic

Treatment Outcome Data 4-5 fold reduction in death rate reduction of drug use reduction of criminal activity engagement in socially productive roles reduced spread of HIV excellent retention (see: Joseph et al, 2000, Mt. Sinai J.Med., vol67, # 5, 6)

Crime among 491 patients before and during MMT at 6 programs Adapted from Ball & Ross - The Effectiveness of Methadone Maintenance Treatment, 1991 Crime Days Per Year Opioid Agonist Treatment of Addiction - Payte

HIV CONVERSION IN TREATMENT HIV infection rates by baseline treatment status. In treatment (IT) n=138, not in treatment (OT) n=88 Source: Metzger, D. et. al. J of AIDS 6:1993. p.1052 Opioid Maintenance Pharmacotherapy - A Course for Clinicians

Other drugs of abuse: how do they affect MMT? Stimulants: patients do poorly Alcohol: additive sedation, complicate Hep C. Benzodiazepines: synergistic sedation THC: no effect on major outcomes Opioids: usually blocked, tolerance

Pregnancy MMT treatment of choice for pregnant, opioid-abusing women. Efforts to avoid intra-uterine fetal withdrawal, including split dose. Neonatal withdrawal occurs within 72 hours, at least 45% need treatment. Breastfeeding recommended if not HIV positive.

Pain in patients on MMT Methadone is prescribed for pain treatment in twice or three times daily doses. Up to 60% of MMT patients have chronic pain (Jamison 2000, Rosenblum 2003) Split doses may be indicated.

Pharmacotherapy in context: correct glossary Abstinence includes pharmacotherapy Maintenance, not substitution or replacement (new term also: MAT) Tapering from maintenance, not detoxification, (also ‘medically supervised withdrawal’, or MSW) Discontinuation, not discharge Toxicology screens: pos/neg, not clean/dirty)

Buprenorphine

A FEW WORDS ABOUT BUPRENORPHINE “Ceiling effect” and safety Displaced other opiates: withdrawal on induction Sublingual tablet Schedule 3(methadone is 2) One form combined with naloxone Office – based use available

Comparison of Activity Levels

Slide: courtesy Reckitt Benkiser

Buprenorphine, Methadone, LAAM: Treatment Retention Percent Retained % Lo Meth 58% Bup 73% Hi Meth 53% LAAM Study Week Johnson et al, 2000

Buprenorphine, Methadone, LAAM: Opioid Urine Results Mean % Negative Study Week All Subjects Lo Meth Bup Hi Meth LAAM % 40% 39% 49%

Effect of counseling in buprenorphine treatment (Fiellin, 2002)

Retention in treatment Treatment duration (days) Remaining in treatment (nr) Control, 6-day detox Buprenorphine maintenance Kakko et al, 2003,

Opioid pharmacotherapy, summary: Methadone, buprenorphine and LAAM all approved by the FDA for treatment of opiate dependence. (LAAM not currently available from any drug company) Best evidence so far supports maintenance. Detoxification attempts should have maintenance as a back up in case of relapse.